Demographics of subjects studied
Patient ID . | Year of birth . | HLA . | Cohort . | Treatment status . | Log HIV RNA copies/mL plasma* . | CD4+ T-cell count/μL* . |
|---|---|---|---|---|---|---|
| AC-02 | 1955 | A11, 29; B8, 44; Cw7, 4 | Acute (STI) | Off | 2.13 | 740 |
| AC-14 | 1953 | A2, 3; B8, 62; Cw7, 10 | Acute (STI) | Off | 3.06 | 774 |
| AC-15 | 1957 | A1, 3; B7, 8; Cw7,- | Acute (STI) | Off | 3.21 | 506 |
| AC-27 | 1939 | A23, 30; B8, 35; Cw4, 7 | Acute | Off | 4.40 | 395 |
| AC-42 | 1956 | A1,-; B8, 18, Cw5, 7 | Acute | On | 1.70 | 818 |
| AC-46 | 1951 | A1, 26; B8, 51; Cw7, 15 | Acute (STI) | On/off | 1.70 | 986 |
| AC-47 | 1974 | A1, 29; B8, 55; Cw3, 7 | Acute | Off | 4.05 | 360 |
| AT-01 | 1966 | A0201, 26; B8, 44; Cw5, 7 | Chronic | Off | 5.47 | 129 |
Patient ID . | Year of birth . | HLA . | Cohort . | Treatment status . | Log HIV RNA copies/mL plasma* . | CD4+ T-cell count/μL* . |
|---|---|---|---|---|---|---|
| AC-02 | 1955 | A11, 29; B8, 44; Cw7, 4 | Acute (STI) | Off | 2.13 | 740 |
| AC-14 | 1953 | A2, 3; B8, 62; Cw7, 10 | Acute (STI) | Off | 3.06 | 774 |
| AC-15 | 1957 | A1, 3; B7, 8; Cw7,- | Acute (STI) | Off | 3.21 | 506 |
| AC-27 | 1939 | A23, 30; B8, 35; Cw4, 7 | Acute | Off | 4.40 | 395 |
| AC-42 | 1956 | A1,-; B8, 18, Cw5, 7 | Acute | On | 1.70 | 818 |
| AC-46 | 1951 | A1, 26; B8, 51; Cw7, 15 | Acute (STI) | On/off | 1.70 | 986 |
| AC-47 | 1974 | A1, 29; B8, 55; Cw3, 7 | Acute | Off | 4.05 | 360 |
| AT-01 | 1966 | A0201, 26; B8, 44; Cw5, 7 | Chronic | Off | 5.47 | 129 |
All subjects were men. Off indicates without antiretroviral treatment during study; on, antiretroviral treatment during study; on/off, treatment interruption; and STI, individual participating in the structural treatment interruption trial.11
At study entry.